12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Aura Biosciences (NASDAQ:AURA) stock moved upwards by 44.3% to $13.0 during Tuesday’s pre-market session. The company’s market…
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.
Why Aura Biosciences Stock Hit A New 52-Week Low Today
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers PaxMedica (NASDAQ:PXMD) stock moved upwards by 84.4% to $5.62 during Tuesday’s regular session. As of 12:31 EST,…
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Senti Biosciences (NASDAQ:SNTI) stock increased by 139.8% to $0.7 during Tuesday’s pre-market session. The market value of…
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Senti Biosciences (NASDAQ:SNTI) shares increased by 187.7% to $0.84 during Monday’s after-market session. Trading volume for this…
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment For CoMpass Phase 3 Clinical Trial Of Belzupacap Sarotalocan In Early-Stage Choroidal Melanoma
Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in